Safety and tolerability of tigecycline for the treatment of complicated skin and soft-tissue and intra-abdominal infections: An analysis based on five European observational studies

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue SUPPL.2, 2013, Pages

  Guirao, Xavier ^a,b   García, Miguel Sánchez ^c   Bassetti, Matteo ^d   Bodmann, Klaus Friedrich ^e   Dupont, Hervé ^f   Montravers, Philippe ^g   Heizmann, Wolfgang R ^h   Capparella, Maria Rita ⁱ   Simoneau, Damien ⁱ   Eckmann, Christian ^j  

^a HOSPITAL GENERAL DE GRANOLLERS   (Spain)

^b UNIVERSITAT INTERNACIONAL DE CATALUNYA   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^e Werner Forssmann Hospital   (Germany)

^f UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h Center for Microbiology and Infectious Diseases   (Germany)

ⁱ PFIZER INC   (United States)

^j Klinikum Peine   (Germany)

more..

Author keywords

Approved indications; Broad spectrum antibacterial therapy; Glycylcycline antibiotics; Non interventional studies; Safety profile

Indexed keywords

TIGECYCLINE;

ABDOMINAL ABSCESS; ABDOMINAL DISEASE; ABDOMINAL INFECTION; ABDOMINAL PAIN; ABSCESS; ADULT; AGED; ANTIBIOTIC THERAPY; APACHE; ARTICLE; BILIRUBIN BLOOD LEVEL; BODY TEMPERATURE; COMORBIDITY; COMPLICATED INTRAABDOMINAL INFECTION; COMPLICATED SKIN AND SOFT TISSUE INFECTION; DEVICE INFECTION; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUODENUM ULCER; FEMALE; FEVER; FRANCE; GENERAL CONDITION DETERIORATION; GERMANY; HEART ARREST; HUMAN; INTENSIVE CARE UNIT; INTESTINE FISTULA; ITALY; KIDNEY FAILURE; LEUKOCYTE COUNT; LIVER FAILURE; LOCALIZED INTRAABDOMINAL FLUID COLLECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; NAUSEA AND VOMITING; PERITONITIS; PNEUMONIA; PROTHROMBIN TIME; RESPIRATORY FAILURE; SEPSIS; SEPTIC SHOCK; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; SPAIN; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREND STUDY;

APPROVED INDICATIONS; BROAD-SPECTRUM ANTIBACTERIAL THERAPY; GLYCYLCYCLINE ANTIBIOTICS; NON-INTERVENTIONAL STUDIES; SAFETY PROFILE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG THERAPY, COMBINATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EUROPE; FEMALE; HUMANS; INTRAABDOMINAL INFECTIONS; MALE; MIDDLE AGED; MINOCYCLINE; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS;

EID: 84879355663     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt143     Document Type: Article

References (36)

1. Andrasevic AT, Dowzicky MJ. In vitro activity of tigecycline and comparators against Gram-negative pathogens isolated from blood in Europe (2004-2009). Int J Antimicrob Agents 2012; 39: 115-23.
2. Dowzicky MJ, Chmelarova E. Global in vitro activity of tigecycline and linezolid against Gram-positive organisms collected between 2004 and 2009. Int J Antimicrob Agents 2011; 37: 562-6.
3. Tygacil Summary of Product Characteristics. Sandwich, Kent, UK: Pfizer Ltd, 2012.
4. Falagas ME, Karageorgopoulos DE, Dimopoulos G. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline. Curr Drug Metab 2009; 10: 13-21.
5. Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis 2005; 41 Suppl 5: S303-14.
6. Tygacil Prescribing Information. Philadelphia, PA, USA: Pfizer Inc., 2011.
7. Muralidharan G, Micalizzi M, Speth J et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005; 49: 220-9.
8. Babinchak T, Ellis-Grosse E, Dartois N, et al. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005; 41 Suppl 5: S354-67.
9. Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycinaztreonam. Clin Infect Dis 2005; 41 Suppl 5: S341-53.
10. Greer ND. Tigecycline (Tygacil): the first in the glycylcycline class of antibiotics. Proc (Bayl Univ Med Cent) 2006; 19: 155-61.
11. US FDA. FDA Drug Safety Communication: Increased Risk of Death With Tygacil (Tigecycline) Compared to Other Antibiotics Used to Treat Similar Infections (1 September 2010). http://www.fda.gov/drugs/drugsafety/ucm224370.htm (26 September 2012, date last accessed).
12. European Medicines Agency. Questions and Answers on the Review of Tygacil (Tigecycline): Outcome of a Renewal Procedure (17 February 2011). http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/human/000644/WC500102228.pdf (22 March 2012, date last accessed).
13. European Medicines Agency. EPAR Summary for the Public: Tygacil (last updated February 2012). http://www.ema.europa.eu/docs/en_GB/document_ library/EPAR_-_Summary_for_the_public/human/000644/WC500044509. pdf (6 November 2012, date last accessed).
14. Cai Y, Wang R, Liang B, et al. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother 2011; 55: 1162-72.
15. Tasina E, Haidich AB, Kokkali S, et al. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis 2011; 11: 834-44.
16. Vardakas KZ, Rafailidis PI, Falagas ME. Effectiveness and safety of tigecycline: focus on use for approved indications. Clin Infect Dis 2012; 54: 1672-4.
17. Yahav D, Lador A, Paul M, et al. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother 2011; 66: 1963-71.
18. Curcio D. Tigecycline for severe infections: the gap between the warning and the necessity. J Antimicrob Chemother 2011; 66: 454-6.
19. Bassetti M, Nicolini L, Repetto E, et al. Tigecycline use in serious nosocomial infections: a drug use evaluation. BMC Infect Dis 2010; 10: 287.
20. Bodmann KF, Heizmann WR, von Eiff C, et al. Therapy of 1,025 severely ill patients with complicated infections in a German multicenter study: safety profile and efficacy of tigecycline in different treatment modalities. Chemotherapy 2012; 58: 282-94.
21. Montravers P, Dupont H, Bedos JP, et al. Use of tigecycline in intensive care: a French prospective observational study. Clin Microbiol Infect 2012; 18: 767-8.
22. Eckmann C, Heizmann WR, Leitner E, et al. Prospective, non-interventional, multi-centre trial of tigecycline in the treatment of severely ill patients with complicated infections: new insights into clinical results and treatment practice. Chemotherapy 2011; 57: 275-84.
23. Sanchez Garcia M, on behalf of the Tigecycline in Critically Ill Patients Study Group. Observational study of the use of tigecycline (TGC) in critically ill patients (CIP). In: Abstracts of the Fifty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 2011. Abstract K-1412. American Society for Microbiology, Washington, DC, USA.
24. Bassetti M, Eckmann C, Bodmann KF, et al. Prescription behaviours for tigecycline in real-life clinical practice from five European observational studies. J Antimicrob Chemother 2013; 68 Suppl 2: ii5-14.
25. Montravers P, Bassetti M, Dupont H, et al. Efficacy of tigecycline for the treatment of complicated skin and soft-tissue infections in real-life clinical practice from five European observational studies. J Antimicrob Chemother 2013; 68 Suppl 2: ii15-24.
26. Eckmann C, Montravers P, Bassetti M, et al. Efficacy of tigecycline for the treatment of complicated intra-abdominal infections in real-life clinical practice from five European observational studies. J Antimicrob Chemother 2013; 68 Suppl 2: ii25-35.
27. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Surg Infect (Larchmt) 2010; 11: 79-109.
28. May AK, Stafford RE, Bulger EM, et al. Treatment of complicated skin and soft tissue infections. Surg Infect (Larchmt) 2009; 10: 467-99.
29. Eron LJ, Lipsky BA, Low DE, et al. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrob Chemother 2003; 52 Suppl 1: i3-17.
30. Swoboda S, Ober M, Hainer C, et al. Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug use evaluation in a surgical intensive care unit. J Antimicrob Chemother 2008; 61: 729-33.
31. Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-29.
32. Gunter OL, Guillamondegui OD, May AK, et al. Outcome of necrotizing skin and soft tissue infections. Surg Infect (Larchmt) 2008; 9: 443-50.
33. Yilmazlar T, Ozturk E, Alsoy A, et al. Necrotizing soft tissue infections: APACHE II score, dissemination, and survival. World J Surg 2007; 31: 1858-62.
34. Berreta J, Kociak D, Balducci A, et al. [Generalized secondary peritonitis: predictors of in-hospital mortality and survival and mortality evolutive links]. Acta Gastroenterol Latinoam 2010; 40: 105-16.
35. Malik AA, Wani KA, Dar LA, et al. Mannheim Peritonitis Index and APACHE II-prediction of outcome in patients with peritonitis. Ulus Travma Acil Cerrahi Derg 2010; 16: 27-32.
36. French Society of Anesthesia and Intensive Care. Scoring Systems for ICU and Surgical Patients: APACHE II (Acute Physiology And Chronic Health Evaluation). http://www.sfar.org/scores2/apache22.html (12 February 2013, date last accessed).